UPDATE 1-Acorda's MS walking drug Q4 sales view beats Street

Mon Jan 10, 2011 11:07am EST

* Sees Q4 Ampyra sales of $55.7 mln

* Sees FY gross sales of $141.4 mln vs est $185.12 mln

* Shares up as much as 9 percent

Jan 10 (Reuters) - Acorda Therapeutics Inc (ACOR.O) forecast better-than-expected quarterly sales view for its drug to treat walking difficulties in patients with multiple sclerosis, sending its shares up 9 percent.

The pharmaceutical company said it expects fourth-quarter sales of $55.7 million from its key drug Ampyra.

In November, Acorda had warned of a decrease in sales for Ampyra, as the number of new patients starting on the drug, which was launched in March, would no longer be augmented by patients from the backlog. [ID:nSGE6A00FY]

Analysts have, since then, revised fourth-quarter sales expectation of Ampyra to $44-$50 million.

The Hawthorne, New York-based company also said it sees gross sales of $141.4 million for the year.

Analysts, on an average, were expecting revenue of $185.12 million for the year, according to Thomson Reuters I/B/E/S.

Acorda shares, which have risen 10 percent since its warning on lower Ampyra sales, were up 7 percent at $29.48 on Monday on Nasdaq. (Reporting by Vidya L Nathan in Bangalore; Editing by Roshni Menon)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.